BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25395418)

  • 1. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
    Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML
    Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
    Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G
    Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
    Sakaguchi H; Okuno Y; Muramatsu H; Yoshida K; Shiraishi Y; Takahashi M; Kon A; Sanada M; Chiba K; Tanaka H; Makishima H; Wang X; Xu Y; Doisaki S; Hama A; Nakanishi K; Takahashi Y; Yoshida N; Maciejewski JP; Miyano S; Ogawa S; Kojima S
    Nat Genet; 2013 Aug; 45(8):937-41. PubMed ID: 23832011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of subclonal SETBP1 and JAK3 mutations in juvenile myelomonocytic leukemia using droplet digital PCR.
    Wakamatsu M; Okuno Y; Murakami N; Miwata S; Kitazawa H; Narita K; Kataoka S; Ichikawa D; Hamada M; Taniguchi R; Suzuki K; Kawashima N; Nishikawa E; Narita A; Nishio N; Kojima S; Muramatsu H; Takahashi Y
    Leukemia; 2021 Jan; 35(1):259-263. PubMed ID: 32307441
    [No Abstract]   [Full Text] [Related]  

  • 5. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.
    Shiba N; Ohki K; Park MJ; Sotomatsu M; Kudo K; Ito E; Sako M; Arakawa H; Hayashi Y
    Br J Haematol; 2014 Jan; 164(1):156-9. PubMed ID: 24117422
    [No Abstract]   [Full Text] [Related]  

  • 6. Somatic SETBP1 mutations in myeloid neoplasms.
    Makishima H
    Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new player SETs in myeloid malignancy.
    Trimarchi T; Ntziachristos P; Aifantis I
    Nat Genet; 2013 Aug; 45(8):846-7. PubMed ID: 23892662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
    Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic SETBP1 mutations in myeloid malignancies.
    Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
    Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
    Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genomic landscape of juvenile myelomonocytic leukemia.
    Stieglitz E; Taylor-Weiner AN; Chang TY; Gelston LC; Wang YD; Mazor T; Esquivel E; Yu A; Seepo S; Olsen S; Rosenberg M; Archambeault SL; Abusin G; Beckman K; Brown PA; Briones M; Carcamo B; Cooper T; Dahl GV; Emanuel PD; Fluchel MN; Goyal RK; Hayashi RJ; Hitzler J; Hugge C; Liu YL; Messinger YH; Mahoney DH; Monteleone P; Nemecek ER; Roehrs PA; Schore RJ; Stine KC; Takemoto CM; Toretsky JA; Costello JF; Olshen AB; Stewart C; Li Y; Ma J; Gerbing RB; Alonzo TA; Getz G; Gruber T; Golub T; Stegmaier K; Loh ML
    Nat Genet; 2015 Nov; 47(11):1326-1333. PubMed ID: 26457647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Linder K; Iragavarapu C; Liu D
    Biomark Res; 2017; 5():33. PubMed ID: 29225884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
    Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
    Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
    PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.